Zyloprim Articles
Majority of gout patients on uric acid lowering therapy fail to achieve control of serum urate levels report
10 June 2012
Several abstracts on gout reveal true burden of disease and highlight promising new treatments
27 May 2011
Regeneron initiates Ph III Arcalyst study
27 March 2009
Japan stock market week to March 16, 2009
23 March 2009
NICE recommends Ipsen drug for gout treatment
12 January 2009
Savient's pegloticase BLA accepted for review by FDA
12 January 2009
ASH hears strong data on Novartis
22 December 2008
Sanofi's Elitek reduces PUA more than allopurinol
15 December 2008
Caraco's generic Zyloprim cleared in USA
10 September 2007
Nabi sells cancer drug Aloprim to Bioniche
30 April 2007
Cardiome's oxypurinol for gout faces delay
5 July 2004
Nabi to acquire full rights to Aloprim
5 July 2004
Second FDA drug imports "blitz" finds 80% come from Canada
9 February 2004
GSK in accord with Kaken on Zyloric
6 January 2003
Counsel Corp to float Faro
16 June 1999
Faro Acquires GW Products For $105 Mill
16 December 1998
Sanofi's Eloxatin Gearing Up For Global Roll-Out
30 June 1998
French Generic Market "Still Weak And Patchy"
16 December 1996
Glaxo Wellcome Faces MBO At Mediterranean Site
27 November 1995
IMPACT OF SWEDISH REFERENCE PRICING PLAN
6 June 1994
NET PROFITS LEAP AT SUMITOMO PHARMA
7 March 1994
IMPACT OF SWEDISH REFERENCE PRICING
10 January 1994
NEW XANTHINE OXIDASE INHIBITOR SYNTHESIZED
10 January 1994
COMBO THERAPY FOR LEISHMANIASIS
16 March 1992
Showing 1-27 of 27 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
